CYDY – Bluebird hits the brakes on LentiGlobin studies, Zynteglo marketing after AML, myelodysplastic syndrome cases spur fresh safety concerns – Endpoints News
Amgen is making a long-awaited move on the M&A side, buying South San Francisco-based Five Prime $FPRX for close to $2 billion and adding a slate of new cancer drugs to the pipeline.
Amgen is paying $38 a share, putting the deal value at $1.9 billion. The stock closed at $21.26 last night, giving investors a 78% premium.
The jewel in the crown of this deal is bemarituzumab, which Amgen describes as a first-in-class, Phase III-ready anti-FGFR2b antibody. Amgen was drawn to the bargaining table by Five Prime’s mid-stage data on gastric cancer, satisfied by PFS and OS data helping to validate FGFR2b as a target. Amgen researchers will now expand on the R&D program in other epithelial cancers, including lung, breast, ovarian and other cancers.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 103,100+ biopharma pros reading Endpoints daily — and it’s free.
CYDY – Bluebird hits the brakes on LentiGlobin studies, Zynteglo marketing after AML, myelodysplastic syndrome cases spur fresh safety concerns – Endpoints News
Tags: CYDY
